Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
194M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
99.9M
-
Shares change
-
+99.9M
-
Total reported value, excl. options
-
$2.7B
-
Value change
-
+$2.7B
-
Number of buys
-
60
-
Price
-
$26.97
Significant Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q2 2019
60 filings reported holding BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share as of Q2 2019.
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 99.9M shares
of 194M outstanding shares and own 51.55% of the company stock.
Largest 10 shareholders include Kohlberg Kravis Roberts & Co. L.P. (36.9M shares), Viking Global Investors LP (26.6M shares), AMERICAN INTERNATIONAL GROUP INC (6.73M shares), PERCEPTIVE ADVISORS LLC (6.71M shares), Aisling Capital Management LP (3.84M shares), FMR LLC (3.02M shares), Cormorant Asset Management, LP (2.78M shares), SC US (TTGP), LTD. (2.54M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (2.35M shares), and HILLHOUSE CAPITAL MANAGEMENT, LTD. (2.04M shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.